Unusual phenotypes in patients with a pathogenic germline variant in *DICER1*

Kateryna Venger¹ · Miriam Elbracht² · Julia Carlens³ · Peter Deutz¹ · Felix Zeppernick^{4,5} · Lisa Lassay¹ · Christian Kratz⁶ · Martin Zenker⁷ · Jung Kim⁸ · Douglas R. Stewart⁸ · Ilse Wieland⁷ · Kris Ann P. Schultz^{9,10} · Nicolaus Schwerk³ · Ingo Kurth² · Udo Kontny¹

Received: 29 September 2020 / Accepted: 20 July 2021
© The Author(s) 2021

Abstract

Pathogenic germline *DICER1* variants are associated with pleuropulmonary blastoma, multinodular goiter, embryonal rhabdomyosarcoma and other tumour types, while mosaic missense *DICER1* variants in the RNase IIIb domain are linked to cause GLOW (global developmental delay, lung cysts, overgrowth, and Wilms' tumor) syndrome. Here, we report four families with germline *DICER1* pathogenic variants in which one member in each family had a more complex phenotype, including skeletal findings, facial dysmorphism and developmental abnormalities. The developmental features occur with a variable expressivity and incomplete penetrance as also described for the neoplastic and dysplastic lesions associated with *DICER1* variants. Whole exome sequencing (WES) was performed on all four cases and revealed no further pathogenic or likely pathogenic dominant, homozygous or compound heterozygous variants in three of them. Notably, a frameshift variant in *ARID1B* was detected in one patient explaining part of her phenotype. This series of patients shows that pathogenic *DICER1* variants may be associated with a broader phenotypic spectrum than initially assumed, including predisposition to different tumours, skeletal findings, dysmorphism and developmental abnormalities, but genetic work up in syndromic patients should be comprehensive in order not to miss additional underlying /modifying causes.

Keywords *DICER1* · Unusual phenotype · Developmental delay · Skeletal findings · Pierre-Robin sequence

Introduction

DICER1 is a member of ribonuclease III (RNaseIII) family and responsible for microRNA processing. Thus, *DICER1* modulates gene expression. Germline pathogenic variants in *DICER1* cause a tumour predisposition syndrome (OMIM 601200), which is characterized by occurrence of

pleuropulmonary blastoma, Sertoli-Leydig cell tumour, cystic nephroma, multinodular goiter, embryonic rhabdomyosarcoma of the cervix uteri and other tumour types [1].

Mosaic somatic missense *DICER1* variants in the RNase IIIb domain are linked to GLOW syndrome, an acronym from the reported core features of global developmental delay, lung cysts, overgrowth, and Wilms' tumour (OMIM

✉ Udo Kontny
ukontny@ukaachen.de

¹ Division of Pediatric Hematology, Oncology and Stem Cell Transplantation, Department of Pediatrics, Medical Faculty, RWTH Aachen University, Aachen, Germany

² Institute of Human Genetics, Medical Faculty, RWTH Aachen University, Aachen, Germany

³ Clinic for Pediatric Pulmonology, Allergology and Neonatology, Hannover Medical School, Hannover, Germany

⁴ Department of Gynecology and Obstetrics, Medical Faculty, RWTH Aachen University, Aachen, Germany

⁵ Department of Obstetrics and Gynecology, University Hospital Giessen, Giessen, Germany

⁶ Clinic for Pediatric Hematology and Oncology, Hannover Medical School, Hannover, Germany

⁷ Institute of Human Genetics, University Hospital Magdeburg, Magdeburg, Germany

⁸ Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Rockville, MD, USA

⁹ International PPB/*DICER1* Registry, Minneapolis, MN, USA

¹⁰ Cancer and Blood Disorders, Children's Minnesota, Minneapolis, MN, USA

618272) [2]. The discussion of whether GLOW syndrome is a separate entity is ongoing; meanwhile some patients with pathogenic germline variants in *DICER1* are reported matching the phenotype of GLOW syndrome and not all mosaic variants in the RNAase IIIb domain lead to the typical GLOW syndrome phenotype but instead are in line with the variable expressivity and reduced penetrance of *DICER1*-associated features [3].

Here, we report four families with germline *DICER1* pathogenic variants. One member in each family had in addition unusual symptoms which could be a hint to a broader phenotypic spectrum.

Patients

Case 1

The first family includes three siblings and their mother. The oldest son was born with severe Pierre-Robin-sequence (Fig. 1A, B), shortening of the left arm and leg and bilateral hip dysplasia. He later developed multiple thyroid nodules. His sister developed ovarian bilateral Sertoli-Leydig cell tumours at age 5. At age 17, she was diagnosed with papillary thyroid carcinoma. The younger brother also developed papillary thyroid carcinoma at age 17. The children's mother developed Sertoli-Leydig cell tumours of both ovaries at age 23. Previously, she had a benign thyroid nodule removed at age 12. Later, she developed a follicular thyroid carcinoma, which was successfully treated with radioiodine therapy. The children's maternal grandmother had developed a renal cell carcinoma, a bone malignancy and thyroid disease, which makes *DICER1* pathogenic variation probable. However, testing in her has not been performed.

Case 2

This female patient was born as the third child to non-consanguineous parents at 39 weeks of gestation. She showed macrosomia, macrocephaly, and dysmorphic facial features

such as a prominent forehead, low set ears, hypertelorism and ptosis. At the age of 3 months she underwent VP-shunt placement for treatment of obstructive hydrocephalus, and Chiari malformation type 1 was noted. At the age of 11 months the patient was diagnosed with Wilms tumour on the left kidney, which was treated with chemotherapy and nephrectomy according to the SIOP 2001 protocol. Large bilateral lung cysts were diagnosed during staging. Lung biopsy showed focal peripheral alveolar cyst formation consistent with congenital cystic adenomatoid malformation type IV. The patient is now 6 years old and shows developmental delay, dystrophy and mild respiratory insufficiency with overall good quality of life. Her family history was unremarkable for *DICER1*-associated tumors or unusual phenotypic features.

Case 3

The third individual was found to have gynandroblastoma at age 16 with features of intermediately differentiated Sertoli-Leydig cell tumour with juvenile granulosa cell tumour components with atypia and features of sclerosing stromal tumour. The tumour was completely resected (FIGO Stage IA) and followed with observation. She also has multinodular goiter, macrocephaly, macroglossia, developmental delay, mild bilateral varus forefoot and multiple atypical nevi. Family history is significant for a sibling with gynandroblastoma and multinodular goiter [4]. Multiple family members have a history of talipes equinovarus. Three years after her ovarian tumour diagnosis, she developed a pituitary microadenoma which later resolved. Chest imaging has shown no lung cysts, however, histoplasmosis was incidentally discovered and successfully treated. She remains alive and well 14 years following resection of her ovarian tumour.

Case 4

The fourth individual was born preterm at 33 weeks of gestation to non-consanguineous parents. She showed mild dysmorphic facial features such as a bulging underlip,

Fig. 1 A, B Front and side view of patient 1 with severe Pierre-Robin-sequence. The swallowing of solid food is hardly possible. C, D Patient 4 with *DICER1* variant and mild facial features,

hypertelorism, flat nasal bridge, macroglossia, high palate and protruding ears (Fig. 1C, D). Tracheomalacia was noted at birth, requiring a tracheostomy for her first 3 years of life. Later, she showed developmental delay, especially in the field of speech. At age 16 she was diagnosed with an embryonic rhabdomyosarcoma of the cervix uteri. Further work-up revealed multiple thyroid nodules, atrophy of both optic nerves and a retrocerebellar arachnoid cyst. The patient was treated with chemotherapy according to the CWS-Guidance 2014 and underwent hysterectomy. Now, 3 years after the end of therapy, she has been in ongoing remission. Family history was unremarkable for tumors or phenotypic abnormalities.

Methods and results

Conventional karyotyping as well as chromosomal whole-genome microarray from peripheral blood lymphocytes revealed normal results.

Whole exome sequencing (WES) in patients 1, 2 and 4 was carried out using a probe-based capture method to enrich the target regions (IDT Coraville, IA, USA). Alignment to the reference genome (hg19 or hg38), variant calling and analysis was performed using an in-house pipeline based on SeqMule and Kggseq. In patient 3, WES was performed on the proband and her mother as previously reported with modification in capture kit, Roche NimbleGen's SeqCap EZ Human Exome Library, v3.0 with 64 Mb of exonic sequence targeted (Roche NimbleGen, Inc., Madison, WI) and sequencer NovaSeq 6000 (Illumina, San Diego, CA). Variants were called using three callers, HaplotypeCaller (version 3.8-1-0-gf15c1c3ef), UnifiedGenotyper (version 3.8-1-0-gf15c1c3ef) and FreeBayes (version v0.9.14-24-gc292036). Variants passed the GATK hard filter (QD < 2.0, FS > 60.0, MQ < 40.0, MQRankSum < -12.5, ReadPosRankSum < -8.0, SOR > 3.0 for

SNV and QD < 2.0, FS > 200.0, ReadPosRankSum < -20.0, SOR > 10.0 for INDEL), ABHet is between 0.2 and 0.8, and called by at least two of three callers.

In case 1, all affected family members carried a heterozygous pathogenic *DICER1* variant c.2307C>G; p.(Tyr769*) (ENST00000393063). However, no further obvious pathogenic variants were detected by whole-exome sequencing (WES).

In case 2, the heterozygous *DICER1* missense variant c.4031C>T; p.(Ser1344Leu) was identified in DNA of blood lymphocytes. This variant is located in the RNase IIIa domain (Fig. 2) and has previously been reported as a somatic mutation in various cancers, including Wilms tumour and as somatic hotspot mutation in uterine cancer [5, 6]. No other obvious pathogenic variants were detected by whole-exome sequencing (WES). Unfortunately, genetic testing could not be performed on patient's parents nor on her two healthy siblings.

In case 3, the heterozygous nonsense variant c.3073G>T; p.(Glu1025*) in *DICER1* was identified in DNA of blood lymphocytes. Exome sequencing the patient did not reveal any other homozygous, compound heterozygous, X-linked or dominant pathogenic or likely pathogenic sequence variants in a gene known to be associated with a human phenotype (by OMIM listing), other than the known pathogenic *DICER1* variant.

In case 4 molecular genetics revealed a heterozygous variant in *DICER1* (Exon 21; c.3234_3237dupTGGC; p.(Val1080Trpfs*12)). This frameshift variant has not been described previously. The *DICER1* variant was inherited from the 50-year-old father without a history of tumours. Interestingly, heterozygosity for a frameshift variant c.5915_5916del, p.(Cys1972Tyrfs*11) (Chr6(GRCh38):g.157206936_157206937del) in *ARID1B* was detected in addition. This variant has not yet been described in the genome variant databases (gnomAD, ClinVar) and is suspected to be pathogenic. The variant was not detected in blood from

Fig. 2 Diagram of *DICER1* variants in the four patients described here

the parents, suggesting a de novo origin. *ARID1B* mutations are associated with autosomal dominant inherited Coffin-Siris syndrome type 1 (OMIM 135900), which may in part explain some of the additional clinical features of the patient.

Discussion

Most germline *DICER1* pathogenic variants are loss-of-function variants (LOF) [1]. LOF variants as in our patients 1, 3 and 4 are not likely to cause skewed miRNA processing, however, one cannot exclude the possibility that developmental defects might arise from *DICER1* haploinsufficiency. Developmental delay and a syndromic phenotype combined with classical *DICER1*-associated tumours have been rarely reported and are described in association with a 14q32 deletion encompassing the *DICER1* locus [7, 8] (Table 1). One female patient with 14q32 deletion showed developmental delay, particularly in the field of speech in combination with mild facial dysmorphism (thick eyebrows, wide nasal base and bulbous nose) [9] as our patient 4 with a frameshift variant in *DICER1* and in *ARID1B*. This similarity of both patients raises the possibility that developmental delay and facial dysmorphism in both patients may be associated with *DICER1*. However, the situation is complicated by the fact that the patient also has the characteristics of Coffin-Siris syndrome and most additional phenotypic features like tracheomalacia and arachnoidal cyst may be well explained by the latter diagnosis [10]. Our patient 4 shows that, nevertheless, it cannot be excluded that in individual cases two rare conditions may occur simultaneously and that a comprehensive molecular genetic diagnosis is necessary in the presence of additional symptomatology.

Developmental delay is also a feature of GLOW syndrome (mosaic *DICER1* variant in the RNase IIIb domain) [2]. There are several similarities between the phenotypes of patient 2 and the two previously published patients with GLOW syndrome such as macrocephaly and macrosomia at birth, Wilms tumour, hydrocephalus, hypertelorism, lung cysts and developmental delay [2]. Unfortunately, segregation analysis in the family of patient 2 could not

be undertaken and thus mosaicism in our patient cannot be ruled out, but allele distribution argues for a germline heterozygous *DICER1* variant. The detected missense variant c.4031C>T; p.(Ser1344Leu) within the RNase IIIa domain has been described so far only as somatic mutation in patients with Wilms tumour and other cancers, but not as germline variant, leaving a rest of uncertainty on the pathogenicity of this variant [11]. Interestingly, mutations within the RNase IIIa domain have been shown to phenocopy mutations in the RNase IIIb domain presumably due to the constrained proximity of the RNase IIIa and RNase IIIb as shown by structural and evolutionary coupling analyses [6]. This constrained proximity could also explain why the presumed germline variant in patient 2 leads to a phenotype similar to the one described in the two patients with GLOW syndrome associated with mosaic *DICER1* mutation in the RNase IIIb domain, suggesting a genotype–phenotype relationship with missense mutations in RNase III. Whether a missense variant as in patient 2 is sufficient to lead to tumor development or a second somatic hit in *DICER1* is needed, as presumed in patients with LOF variants, remains speculative.

Pierre-Robin sequence and other skeletal abnormalities as described in patient 1 may also be a rare phenotypic presentation of a *DICER1* variant. Pierre-Robin sequence is a craniofacial anomaly which includes mandibular hypoplasia, glossoptosis and often cleft palate. There are several genetic causes leading to this phenotype [12]. Interestingly, *DICER1* has been shown to play a role in nucleolar function, and heterozygous pathogenic variants in genes involved in nucleolar homeostasis have been identified to cause various craniofacial disorders [13, 14]. One case of Pierre-Robin sequence associated with *DICER1* variant was previously described [15]. In mice, a conditional *Dicer1* deletion leads to late embryonic lethality and severe craniofacial dysmorphism, including a secondary cleft palate [16].

Abnormalities in optic nerves as in patient 4 were previously described in patients with *DICER1* germline variants [17]. In a mouse model, conditional *Dicer1* deletion in the retina led to developmental disorder of retinal cells [18]. Although ocular involvement has to be discussed in

Table 1 Patients with *DICER1* variants and syndromic features described in the literature

Phenotype	<i>DICER1</i> mutation or deletions including <i>DICER1</i>
6-year-old male, developmental delay, hypotonia, macrocephaly, obesity, and behavioral problems [8] Mother: bilateral multinodular goiter and papillary thyroid carcinoma [8]	1,4 MB deletion 14q32
15-year-old female, autism, coarse facial features, Sertoli-Leydig cell tumour, and Wilms' tumour [8]	5 MB deletion 14q32
4-year-old male, developmental delay, congenital dysmorphic features, cystic nephroma, ciliary body medulloepithelioma, cerebral sarcoma, lung cyst, bifid uvula [9]	5,82 MB deletion 14q32
Male patient with Pierre-Robin sequence [15]	<i>DICER1</i> -mutation: p.(Tyr1511*)

this patient in context of the identified *ARID1B* variant, in Coffin-Siris syndrome ocular findings are more likely to manifest as strabismus, nystagmus, cataract, hypophoria, astigmatism, hypermetropia and anisomyopia [19], with optic nerve hypoplasia being described only occasionally [20].

In summary, germline pathogenic *DICER1* variants may not only be associated with the occurrence of certain tumour types, but might also rarely include developmental features, like Pierre-Robin sequence, developmental delay, facial dysmorphisms, and ocular abnormalities. Actually, it is rather surprising that *DICER1* pathogenic germline variants do not lead to an even more severe clinical phenotype, since *DICER1* is an absolutely central molecule in RNA interference: Dicer catalyses the first step of RNA interference and initiates the formation of the RNA-induced silencing complex (RISC), where argonaute endonuclease, is able to degrade mRNA whose sequence is complementary to the resulting siRNA. Due to this fundamental mechanism, effects in all kinds of cells are conceivable. Nevertheless, we acknowledge that the role of concomitant pathogenic variants in other genes cannot be ruled out, or may indeed modify the phenotype such as in patient 4. The coincidence of developmental phenotypes and pathogenic *DICER1* variant merits further evaluation.

Acknowledgements We thank Mrs. Ute Stahlberg for editorial assistance. We thank Laura Harney, BSN, RN, Ann G. Carr, MS, CGC and Esteban Astiazaran Symonds, MD for their clinical assistance. We acknowledge the role of the Cancer Genetics Research Laboratory of the Division of Cancer Epidemiology and Genetics of the U.S. National Cancer Institute for generating exome data, especially Bin Zhu, Ph.D and Dongjing Wu, MS, MS. This work used the computational resources of the NIH High Performance Computing Biowulf cluster and was created in cooperation with the Treatment and Research Center for Rare Hereditary Tumor Diseases at the Center for Rare Diseases Aachen (ZSEA) and the Interdisciplinary Oncology Project Group for Hereditary Tumor Syndromes (IOP ETS) at the Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD).

Author contributions KV, ME, NS, KAS, and UK, wrote the manuscript. PD, JC, FZ, LL collected the data, DRS, JK, IK, IW, MZ performed the genetic analysis, CK, IK and UK supervised the management and follow up of the case. All authors revised and approved the final manuscript and agreed to be accountable for the content of the work.

Funding Open Access funding enabled and organized by Projekt DEAL. This work was supported in part by the Intramural Research Program of the Division of Cancer Epidemiology and Genetics of the National Cancer Institute, Bethesda, MD. The International PPB/*DICER1* Registry is supported by Children's Minnesota Foundation and Pine Tree Apple Classic Fund. KAS receives grant support from the National Institutes of Health/National Cancer Institute Grant 1R37CA244940. CPK has been supported by the Deutsche Kinderkrebsstiftung (DKS2019.13).

Data availability The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

Declarations

Conflict of interest DRS performs contract clinical telegenetics work for Genome Medical, Inc in accordance with relevant NCI ethics policies. All other authors declare that they have no competing financial interests in relation to the work described.

Ethical approval This research study was conducted retrospectively from data obtained for clinical purposes. Approval was obtained from the ethics committee of the Uniklinik RWTH Aachen (EK 328/20).

Informed consent Written informed consent was obtained from patients / minor(s)' legal guardian for the publication of any potentially identifiable images included in this article.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

References

- Slade I, Bacchelli C, Davies H, Murray A, Abbaszadeh F, Hanks S et al (2011) *DICER1* syndrome: clarifying the diagnosis, clinical features and management implications of a pleiotropic tumour predisposition syndrome. *J Med Genet* 48:273278. <https://doi.org/10.1136/jmg.2010.083790>
- Klein S, Lee H, Ghahremani S, Kempert P, Ischander M, Teitell MA et al (2014) Expanding the phenotype of mutations in *DICER1*: mosaic missense mutations in the RNase IIIb domain of *DICER1* cause GLOW syndrome. *J Med Genet* 51:294–302. <https://doi.org/10.1136/jmedgenet-2013-101943>
- de Kock L, Wu MK, Foulkes WD (2019) Ten years of *DICER1* mutations: provenance, distribution, and associated phenotypes. *Hum Mutat* 40:1939–1953. <https://doi.org/10.1002/humu.23877>
- Schultz KA, Pacheco MC, Yang J, Williams GM, Messinger Y, Hill DA et al (2011) Ovarian sex cord-stromal tumors, pleuropulmonary blastoma and *DICER1* mutations: a report from the International Pleuropulmonary Blastoma Registry. *Gynecol Oncol* 122:246–250. <https://doi.org/10.1016/j.ygyno.2011.03.024>
- Gadd S, Huff V, Walz AL, Ooms AHAG, Armstrong AE, Gerhard DS et al (2017) A Children's Oncology Group and TARGET initiative exploring the genetic landscape of Wilms tumor. *Nat Genet* 49:1487–1494. <https://doi.org/10.1038/ng.3940>
- Vedanayagam J, Chatila WK, Aksoy BA, Majumdar S, Skanderup AJ, Demir E et al (2019) Cancer-associated mutations in *DICER1* RNase IIIa and IIIb domains exert similar effects on miRNA biogenesis. *Nat Commun* 10:3682. <https://doi.org/10.1038/s41467-019-11610-1>
- Herriges JC, Brown S, Longhurst M, Ozmore J, Moeschler JB, Janze A et al (2019) Identification of two 14q32 deletions involving *DICER1* associated with the development of *DICER1*-related tumors. *Eur J Med Genet* 62:9–14. <https://doi.org/10.1016/j.ejmg.2018.04.011>

8. de Kock L, Geoffrion D, Rivera B, Wagener R, Sabbaghian N, Bens S et al (2018) Multiple DICER1-related tumors in a child with a large interstitial 14q32 deletion. *Genes Chromosom Cancer* 57:223–230. <https://doi.org/10.1002/gcc.22523>
9. Ting TW, Brett MS, Cham BW, Lim JY, Law HY, Tan EC et al (2016) DICER1 deletion and 14q32 microdeletion syndrome: an additional case and a review of the literature. *Clin Dysmorphol* 25:37–40. <https://doi.org/10.1097/MCD.0000000000000105>
10. Santen G, Vries B, Dingemans L (2021) ARID1B. In: Human disease genes—website series <https://humandiseasegenes.nl/arid1b/graph-and-chart/>
11. Wu MK, Sabbaghian N, Xu B, Addidou-Kalucki S, Bernard C, Zou D, Reeve AE et al (2013) Biallelic DICER1 mutations occur in Wilms tumours. *J Pathol* 230:154–164. <https://doi.org/10.1002/path.4196>
12. Logies R, Breugem C, van Haaften G, Paes E, Sperber G, van den Boogaard MJ, Farlie PG (2018) The ontogeny of Robin sequence. *Am J Med Genet A* 176:1349–1368. <https://doi.org/10.1002/ajmg.a.38718>
13. Roche B, Arcangioli B, Martienssen R (2017) New roles for Dicer in the nucleolus and its relevance to cancer. *Cell Cycle* 16:1643–1653. <https://doi.org/10.1080/15384101.2017.1361568>
14. Calo E, Gu B, Bowen ME, Aryan F, Zalc A, Liang J et al (2018) Tissue-selective effects of nucleolar stress and rDNA damage in developmental disorders. *Nature* 554:112–117. <https://doi.org/10.1038/nature25449>
15. Lee DJ, Stroe I, MS, Parsley KL (2016) Spectrum of presentations in DICER1 hereditary cancer syndrome. Abstract 317, ACMG Annual Clinical Genetics Meeting 2016, Tampa, FL
16. Barritt LC, Miller JM, Scheetz LR, Gardner K, Pierce ML, Soukup GA et al (2012) Conditional deletion of the human ortholog gene Dicer1 in Pax2-Cre expression domain impairs orofacial development. *Indian J Hum Genet* 18:310–319. <https://doi.org/10.4103/0971-6866.107984>
17. Huryn LA, Turriff A, Harney LA, Carr AG, Chevez-Barrios P, Gombos DS et al (2019) DICER1 syndrome: characterization of the ocular phenotype in a family-based cohort study. *Ophthalmology* 126:296–304. <https://doi.org/10.1016/j.ophtha.2018.09.038>
18. Georgi SA, Reh TA (2010) Dicer is required for the transition from early to late progenitor state in the developing mouse retina. *J Neurosci* 30:4048–4061. <https://doi.org/10.1523/JNEUROSCI.4982-09.2010>
19. Pallotta R (1985) Ocular anomalies in Coffin-Siris syndrome. *Ophthalmic Paediatr Genet* 6:349–352
20. van der Sluijs PJ, Jansen S, Vergano SA et al (2019) The ARID1B spectrum in 143 patients: from nonsyndromic intellectual disability to Coffin-Siris syndrome. *Genet Med* 21:1295–1307. <https://doi.org/10.1038/s41436-018-0330-z>

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.